托法替布片联合甲氨蝶呤片治疗银屑病关节炎的临床效果及安全性

doi:10.20047/j.issn1673-7210.2022.28.34

Abstract
Figure/Table
References (22)
Related Citation (15)

Download: PDF (547 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical efficacy and safety of Tofacitinib Tablets combined with Methotrexate Tablets in the treatment of psoriatic arthritis (PsA). Methods A total of 62 patients with PsA admitted to the Department of Rheumatology or Ward, Yuyao People’s Hospital of Zhejiang Province from January 2018 to June 2019 were selected, they were divided into observation group (31 cases) and control group (31 cases) according to the random number table method. The observation group was treated with Tofacitinib Tablets combined with Methotrexate Tablets, the control group was treated with Methotrexate Tablets combined with Leflunomide Tablets, the total course of treatment was 24 weeks. The clinical effect and safety of two groups were observed at different time points. Results After 4 and 12 weeks of treatment, the observation group reached the American College of Rheumatology standard 20% improvement rate was higher than that of the control group (P < 0.05). After 8 weeks of treatment, the visual analogue scale (VAS) score of observation group was lower than that of control group (P < 0.05); after 12 weeks of treatment, tender joint count (TJC), swollen joints count, and VAS score in observation group were lower than those in control group (P < 0.05); after 16 weeks of treatment, TJC in observation group was lower than that of control group; after 16 and 24 weeks of treatment, the VAS score and health assessment questionnaire score of observation group were lower than those of control group (P < 0.05). The total incidence of adverse reactions in observation group was lower than that in the control group (P < 0.05). Conclusion Tofacitib Tablets combined with Methotrexate Tablets and Flunomide Tablets combined with Methotrexate Tablets have the same effect in the treatment of PsA, which can reduce adverse reactions and improve the quality of life of patients.

Key words： Tofacitinib Methotrexate Psoriatic arthritis Security

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZOU Wei ZHU Yingjun SHEN Mengda HAN Wei WEI Wei▲

Cite this article:

ZOU Wei ZHU Yingjun SHEN Mengda HAN Wei WEI Wei▲. Clinical efficacy and safety of Tofacitinib Tablets combined with Methotrexate Tablets in the treatment of psoriatic arthritis[J]. 中国医药导报, 2022, 19(28): 151-153,157.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2022.28.34 OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I28/151

[1] 陆超凡，冷晓梅，曾小峰.中轴型银屑病关节炎研究进展[J].中华内科杂志，2021，60（12）：1180-1183.
[2] 杨大伟，李莹，李志军.银屑病关节炎的诊断及治疗[J].中华全科医学，2020，18（9）：1437-1438.
[3] 张霓.甲氨蝶呤在银屑病治疗中的临床疗效及药物安全性[J].皮肤病与性病，2020，42（1）：59-60.
[4] 杨霞.艾拉莫德联合甲氨蝶呤治疗难治性类风湿关节炎的效果观察[J].现代医学与健康研究（电子版），2021，5（20）：4-7.
[5] 赵丽.益赛普联合甲氨蝶呤治疗银屑病关节炎的疗效观察[J].中国冶金工业医学杂志，2020，37（5）：605-606.
[6] 陈俊杰.沙利度胺联合甲氨蝶呤治疗银屑病关节炎的临床效果观察[J].北方药学，2021，18（3）：156-157.
[7] Gossec L，Smolen JS，Ramiro S，et al. European League Against Rheumatism（EULAR）recommendations for the management of psoriatic arthritis with pharmacological therapies：2015 update [J]. Ann Rheum Dis，2016，75（3）：499-510.
[8] Coates LC，Kavanaugh A，Mease PJ，et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis [J]. Arthritis Rheumatol，2016，68（5）：1060-1071.
[9] Chen M，Dai SM. A novel treatment for psoriatic arthritis：Janus kinase inhibitors [J]. Chin Med J （Engl），2020，133（8）：959-967.
[10] 沈盛县（摘译），王刚（审校）.托法替尼（tofacitinib）治疗关节病性银屑病[J].实用皮肤病学杂志，2019（6）：336.
[11] Moll JM，Wright V. Psoriatic arthritis [J]. Semin Arthritis Rheum，1973，3（1）：55-78.
[12] Kolasinski SL，Neogi T，Hochberg MC，et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand，Hip，and Knee [J]. Arthritis Care Res（Hoboken），2020， 72（2）：149-162.
[13] 张改连，黄烽，张江林，等.来氟米特与甲氨蝶呤治疗银屑病关节炎关节病变的临床研究[J].中华内科杂志，2009， 48（7）：570-574.
[14] Ye W，Hackett S，Vandevelde C，et al. Measuring Physical Function in Psoriatic Arthritis：Comparing the Multidimensional Health Assessment Questionnaire to the Health Assessment Questionnaire-Disability Index [J]. J Rheumatol，2021，48（11）：1686-1691.
[15] Nash P，Coates LC，Fleischmann R，et al. Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis：Pooled Analysis of Two Phase 3 Studies [J]. Rheumatol Ther，2018，5（2）：567-582.
[16] 赵相卓，李连菊，王颖，等.托法替布联合甲氨蝶呤治疗类风湿性关节炎的效果及对血清14-3-3η蛋白、RF的影响[J].中外医学研究，2022，20（11）：47-50.
[17] Mease PJ，Gladman DD，Collier DH，et al. Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis：Primary Results From a Randomized，Controlled Phase Ⅲ Trial [J]. Arthritis Rheumatol，2019， 71（7）：1112-1124.
[18] Abdulrahim H，Sharlala H，Adebajo AO. An evaluation of tofacitinib for the treatment of psoriatic arthritis [J]. Expert Opin Pharmacother，2019，20（16）：1953-1960.
[19] Paik J，Deeks ED. Tofacitinib：A Review in Psoriatic Arthritis [J]. Drugs，2019，79（6）：655-663.
[20] Gratacos Masmitja J，Gonzalez Fernandez CM，Gomez Castro S，et al. Efficacy of Tofacitinib in the Treatment of Psoriatic Arthritis：A Systematic Review [J]. Adv Ther，2021，38（2）：868-884.
[21] Ly K，Beck KM，Smith MP，et al. Tofacitinib in the management of active psoriatic arthritis：patient selection and perspectives [J]. Psoriasis（Auckl），2019，9：97-107.
[22] Kivitz AJ，Fitzgerald O，Nash P，et al. Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis：post hoc exploratory analysis from two phase Ⅲ trials [J]. Clin Rheumatol，2022，41（2）：499-511.